Metastatic Castration-resistant Prostate Cancer Clinical Trials in Salt Lake City, Utah

4 studies are recruiting for metastatic castration-resistant prostate cancer in Salt Lake City, Utah right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

   The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Salt Lake City, Utah

   Locations

   132 in total

   Run by

   AstraZeneca

   See if you can join NCT07611110 on ClinicalTrials.gov

2. Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

   This is an open-label, phase 1b dose-escalation study of cabozantinib in combination with 177Lu-PSMA-617 in subjects with mCRPC. The primary hypothesis is that cabozantinib with 177Lu-PSMA will be safe and have efficacy in patients with mCRPC. The dose-escalation phase (Part 1) will assess the rate…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah

   Run by

   University of Utah

   See if you can join NCT05613894 on ClinicalTrials.gov

3. The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

   The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Intermountain Health, Salt Lake City, Utah

   Locations

   33 in total

   Run by

   Telix Pharmaceuticals (Innovations) Pty Limited

   See if you can join NCT06520345 on ClinicalTrials.gov

4. XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

   The purpose of this study is to determine how well the study drug XL092 is helping to treat a participant's cancer after 16 weeks of treatment. Researchers will also look at how safe the XL092 is and how well the XL092 is working. XL092 is an oral tablet that will be taken once a day. Participants …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah

   Run by

   University of Utah

   See if you can join NCT06568562 on ClinicalTrials.gov